Recent policies reaffirm China’s goal to further enhance patients’ access and signal certain reform directions in the future. Noteworthy policy items include:

  • Premier Li Keqiang announced three tasks to promote patient access to anti-cancer drugs and reduce drug prices
  • NDRC and MOFCOM released Negative List 2018 Version
  • SDA released 2017 Drug Inspection Report
  • SMIA Director General visited Sanming and called for the nationwide promotion of Sanming’s medical insurance reform
  • MOJ released the Amendment of Regulations for the Supervision and Administration of Medical Devices (draft-for-review) for public comment

The latest issue could be downloaded Here.

Leave a comment